Regeneron Pharmaceuticals REGN Outside United States — Property, plant, and equipment, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization.
The official record: Regeneron Pharmaceuticals’s 10-K, filed February 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's outside united states — property, plant, and equipment, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's outside united states — property, plant, and equipment, net?
- Regeneron Pharmaceuticals (REGN) reported outside united states — property, plant, and equipment, net of $788M in Q4 2025.
- What does outside united states — property, plant, and equipment, net mean?
- The total value of the company's physical assets, such as buildings and equipment, located outside of its home country after accounting for depreciation.
- How do you interpret outside united states — property, plant, and equipment, net?
- An increase suggests expansion of international manufacturing or research capacity, while a decrease may indicate asset divestiture, impairment, or a shift toward third-party contract manufacturing models.
- How does outside united states — property, plant, and equipment, net compare across companies?
- Peers in the pharmaceutical industry typically report similar geographic splits of fixed assets to demonstrate their global manufacturing strategy and reliance on international production hubs.